Simvastatin 80 mg appears to be superior to atorvastatin 80 mg in increasing high density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A-1 levels.
Results of the multicentre, randomized, double-blind, parallel-group “Comparative HDL-C Efficacy and Safety Study” (CHESS) were presented here at the 24th Congress of the European Society of Cardiology.
Researchers from Baylor College of Medicine, in Houston, Texas, and Merck & Co., Inc., in West Point, Pennsylvania, United States, led by Christie Ballantyne, enrolled 917 patients with hypercholesterolaemia.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!